2018 Q3 Form 10-Q Financial Statement
#000156459018028612 Filed on November 08, 2018
Income Statement
| Concept | 2018 Q3 | 2017 Q3 |
|---|---|---|
| Revenue | $21.18M | $12.19M |
| YoY Change | 73.77% | -2.28% |
| Cost Of Revenue | $8.887M | $5.210M |
| YoY Change | 70.58% | 100.08% |
| Gross Profit | $12.30M | $6.980M |
| YoY Change | 76.17% | -29.29% |
| Gross Profit Margin | 58.05% | 57.26% |
| Selling, General & Admin | $11.15M | $7.290M |
| YoY Change | 52.92% | -15.53% |
| % of Gross Profit | 90.66% | 104.44% |
| Research & Development | $3.868M | $2.960M |
| YoY Change | 30.68% | 1.02% |
| % of Gross Profit | 31.45% | 42.41% |
| Depreciation & Amortization | $1.010M | $920.0K |
| YoY Change | 9.78% | -16.36% |
| % of Gross Profit | 8.21% | 13.18% |
| Operating Expenses | $15.02M | $10.85M |
| YoY Change | 38.4% | -5.24% |
| Operating Profit | -$2.719M | -$3.870M |
| YoY Change | -29.74% | 145.09% |
| Interest Expense | -$408.0K | -$10.28M |
| YoY Change | -96.03% | -1909.86% |
| % of Operating Profit | ||
| Other Income/Expense, Net | -$17.54M | -$320.0K |
| YoY Change | 5381.56% | 146.15% |
| Pretax Income | -$20.26M | -$14.47M |
| YoY Change | 40.01% | 240.63% |
| Income Tax | -$300.0K | -$180.0K |
| % Of Pretax Income | ||
| Net Earnings | -$19.97M | -$14.27M |
| YoY Change | 39.96% | 279.06% |
| Net Earnings / Revenue | -94.27% | -117.04% |
| Basic Earnings Per Share | -$0.54 | -$0.63 |
| Diluted Earnings Per Share | -$0.54 | -$0.63 |
| COMMON SHARES | ||
| Basic Shares Outstanding | 37.15M shares | 22.53M |
| Diluted Shares Outstanding | 37.15M shares | 22.53M |
Balance Sheet
| Concept | 2018 Q3 | 2017 Q3 |
|---|---|---|
| SHORT-TERM ASSETS | ||
| Cash & Short-Term Investments | $26.20M | $6.000M |
| YoY Change | 336.67% | -73.09% |
| Cash & Equivalents | $26.20M | $15.53M |
| Short-Term Investments | ||
| Other Short-Term Assets | $1.500M | $1.500M |
| YoY Change | 0.0% | 87.5% |
| Inventory | $4.621M | $6.200M |
| Prepaid Expenses | ||
| Receivables | $9.641M | $3.300M |
| Other Receivables | $0.00 | $0.00 |
| Total Short-Term Assets | $41.94M | $16.90M |
| YoY Change | 148.18% | -51.88% |
| LONG-TERM ASSETS | ||
| Property, Plant & Equipment | $3.022M | $2.300M |
| YoY Change | 31.39% | -30.41% |
| Goodwill | $12.01M | |
| YoY Change | ||
| Intangibles | $34.28M | |
| YoY Change | ||
| Long-Term Investments | ||
| YoY Change | ||
| Other Assets | $200.0K | $9.600M |
| YoY Change | -97.92% | 31900.0% |
| Total Long-Term Assets | $49.46M | $58.19M |
| YoY Change | -15.01% | -13.1% |
| TOTAL ASSETS | ||
| Total Short-Term Assets | $41.94M | $16.90M |
| Total Long-Term Assets | $49.46M | $58.19M |
| Total Assets | $91.40M | $75.09M |
| YoY Change | 21.72% | -26.45% |
| SHORT-TERM LIABILITIES | ||
| YoY Change | ||
| Accounts Payable | $2.700M | $3.400M |
| YoY Change | -20.59% | -1.85% |
| Accrued Expenses | $9.600M | $8.600M |
| YoY Change | 11.63% | -29.51% |
| Deferred Revenue | ||
| YoY Change | ||
| Short-Term Debt | $0.00 | $0.00 |
| YoY Change | ||
| Long-Term Debt Due | $200.0K | $15.00M |
| YoY Change | -98.67% | -16.21% |
| Total Short-Term Liabilities | $15.80M | $31.00M |
| YoY Change | -49.03% | -21.73% |
| LONG-TERM LIABILITIES | ||
| Long-Term Debt | $13.40M | $21.17M |
| YoY Change | -36.71% | 149.22% |
| Other Long-Term Liabilities | $1.518M | $1.313M |
| YoY Change | 15.61% | -87.25% |
| Total Long-Term Liabilities | $1.518M | $22.49M |
| YoY Change | -93.25% | 164.68% |
| TOTAL LIABILITIES | ||
| Total Short-Term Liabilities | $15.80M | $31.00M |
| Total Long-Term Liabilities | $1.518M | $22.49M |
| Total Liabilities | $47.06M | $75.27M |
| YoY Change | -37.48% | 56.48% |
| SHAREHOLDERS EQUITY | ||
| Retained Earnings | -$308.1M | -$236.4M |
| YoY Change | 30.35% | |
| Common Stock | $356.5M | $238.2M |
| YoY Change | 49.63% | |
| Preferred Stock | ||
| YoY Change | ||
| Treasury Stock (at cost) | ||
| YoY Change | ||
| Treasury Stock Shares | ||
| Shareholders Equity | $44.39M | -$311.0K |
| YoY Change | ||
| Total Liabilities & Shareholders Equity | $91.45M | $75.09M |
| YoY Change | 21.78% | -26.45% |
Cashflow Statement
| Concept | 2018 Q3 | 2017 Q3 |
|---|---|---|
| OPERATING ACTIVITIES | ||
| Net Income | -$19.97M | -$14.27M |
| YoY Change | 39.96% | 279.06% |
| Depreciation, Depletion And Amortization | $1.010M | $920.0K |
| YoY Change | 9.78% | -16.36% |
| Cash From Operating Activities | $390.0K | -$2.220M |
| YoY Change | -117.57% | 85.0% |
| INVESTING ACTIVITIES | ||
| Capital Expenditures | -$620.0K | -$10.00K |
| YoY Change | 6100.0% | -97.14% |
| Acquisitions | ||
| YoY Change | ||
| Other Investing Activities | $0.00 | -$970.0K |
| YoY Change | -100.0% | |
| Cash From Investing Activities | -$610.0K | -$980.0K |
| YoY Change | -37.76% | 180.0% |
| FINANCING ACTIVITIES | ||
| Cash Dividend Paid | ||
| YoY Change | ||
| Common Stock Issuance & Retirement, Net | ||
| YoY Change | ||
| Debt Paid & Issued, Net | ||
| YoY Change | ||
| Cash From Financing Activities | 10.20M | 110.0K |
| YoY Change | 9172.73% | -98.35% |
| NET CHANGE | ||
| Cash From Operating Activities | 390.0K | -2.220M |
| Cash From Investing Activities | -610.0K | -980.0K |
| Cash From Financing Activities | 10.20M | 110.0K |
| Net Change In Cash | 9.980M | -3.090M |
| YoY Change | -422.98% | -160.23% |
| FREE CASH FLOW | ||
| Cash From Operating Activities | $390.0K | -$2.220M |
| Capital Expenditures | -$620.0K | -$10.00K |
| Free Cash Flow | $1.010M | -$2.210M |
| YoY Change | -145.7% | 160.0% |
Facts In Submission
| Frame | Concept Type | Concept / XBRL Key | Value | Unit |
|---|---|---|---|---|
| dei |
Entity Small Business
EntitySmallBusiness
|
true | ||
| CY2018Q3 | us-gaap |
Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
|
34284000 | |
| CY2018Q3 | us-gaap |
Goodwill
Goodwill
|
12005000 | |
| CY2018Q3 | us-gaap |
Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
|
192000 | |
| CY2018Q3 | us-gaap |
Deferred Revenue Current
DeferredRevenueCurrent
|
39000 | |
| CY2018Q3 | cdna |
Business Acquisition Deferred Payment Consideration With Interest Accretion Current Portion
BusinessAcquisitionDeferredPaymentConsiderationWithInterestAccretionCurrentPortion
|
367000 | |
| CY2018Q3 | us-gaap |
Derivative Liabilities Current
DerivativeLiabilitiesCurrent
|
0 | |
| CY2018Q3 | us-gaap |
Deferred Tax Liabilities Noncurrent
DeferredTaxLiabilitiesNoncurrent
|
3447000 | |
| CY2018Q3 | us-gaap |
Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
|
11612000 | |
| CY2018Q3 | us-gaap |
Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
|
1518000 | |
| CY2018Q3 | us-gaap |
Minority Interest
MinorityInterest
|
0 | |
| CY2018Q3 | us-gaap |
Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
|
44388000 | |
| CY2018Q3 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
91446000 | |
| dei |
Entity Ex Transition Period
EntityExTransitionPeriod
|
true | ||
| dei |
Entity Emerging Growth Company
EntityEmergingGrowthCompany
|
true | ||
| CY2018Q3 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
26202000 | |
| CY2018Q3 | us-gaap |
Accounts Receivable Net Current
AccountsReceivableNetCurrent
|
9641000 | |
| CY2018Q3 | us-gaap |
Inventory Net
InventoryNet
|
4621000 | |
| CY2018Q3 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
1479000 | |
| CY2018Q3 | us-gaap |
Assets Current
AssetsCurrent
|
41943000 | |
| CY2018Q3 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
3022000 | |
| CY2018Q3 | us-gaap |
Liabilities
Liabilities
|
47058000 | |
| CY2018Q3 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
0 | |
| CY2018Q3 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
0 | |
| CY2018Q3 | us-gaap |
Common Stock Value
CommonStockValue
|
39000 | |
| CY2018Q3 | us-gaap |
Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
|
356427000 | |
| CY2018Q3 | us-gaap |
Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
|
-3988000 | |
| CY2018Q3 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-308090000 | |
| CY2018Q3 | us-gaap |
Stockholders Equity
StockholdersEquity
|
44388000 | |
| CY2017Q4 | cdna |
Business Acquisition Deferred Payment Consideration With Interest Accretion Current Portion
BusinessAcquisitionDeferredPaymentConsiderationWithInterestAccretionCurrentPortion
|
407000 | |
| CY2018Q3 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
10000000 | |
| CY2018Q3 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
38784111 | |
| CY2017Q3 | us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
12191000 | |
| CY2018Q3 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.001 | |
| CY2018Q3 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
100000000 | |
| CY2018Q3 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
38784111 | |
| CY2018Q3 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
0 | |
| CY2018Q3 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
0 | |
| CY2018Q3 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.001 | |
| us-gaap |
Share Based Compensation
ShareBasedCompensation
|
5078000 | ||
| CY2018Q3 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
26394000 | |
| us-gaap |
Depreciation And Amortization
DepreciationAndAmortization
|
3039000 | ||
| us-gaap |
Cost Of Goods And Services Sold Depreciation
CostOfGoodsAndServicesSoldDepreciation
|
224000 | ||
| us-gaap |
Cost Of Goods And Services Sold Depreciation
CostOfGoodsAndServicesSoldDepreciation
|
329000 | ||
| cdna |
Loss On Conversion Of Debt To Shares Of Common Stock
LossOnConversionOfDebtToSharesOfCommonStock
|
2806000 | ||
| cdna |
Loss On Conversion Of Debt To Shares Of Common Stock
LossOnConversionOfDebtToSharesOfCommonStock
|
0 | ||
| us-gaap |
Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
|
2188000 | ||
| us-gaap |
Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
|
2772000 | ||
| us-gaap |
Share Based Compensation
ShareBasedCompensation
|
1316000 | ||
| us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
3830000 | ||
| us-gaap |
Increase Decrease In Inventories
IncreaseDecreaseInInventories
|
-358000 | ||
| us-gaap |
Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
|
174000 | ||
| us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
-863000 | ||
| us-gaap |
Increase Decrease In Accrued Salaries
IncreaseDecreaseInAccruedSalaries
|
3376000 | ||
| us-gaap |
Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
|
459000 | ||
| us-gaap |
Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
|
-857000 | ||
| us-gaap |
Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
|
-29000 | ||
| us-gaap |
Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
|
-22000 | ||
| us-gaap |
Increase Decrease In Deferred Income Taxes
IncreaseDecreaseInDeferredIncomeTaxes
|
1168000 | ||
| us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-6005000 | ||
| us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-12157000 | ||
| us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
1075000 | ||
| us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
100000 | ||
| us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-6969000 | ||
| us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-1069000 | ||
| us-gaap |
Proceeds From Debt Net Of Issuance Costs
ProceedsFromDebtNetOfIssuanceCosts
|
14282000 | ||
| us-gaap |
Proceeds From Debt Net Of Issuance Costs
ProceedsFromDebtNetOfIssuanceCosts
|
24002000 | ||
| us-gaap |
Proceeds From Stock Plans
ProceedsFromStockPlans
|
32000 | ||
| us-gaap |
Proceeds From Stock Plans
ProceedsFromStockPlans
|
93000 | ||
| us-gaap |
Repayments Of Long Term Debt And Capital Securities
RepaymentsOfLongTermDebtAndCapitalSecurities
|
11397000 | ||
| us-gaap |
Repayments Of Long Term Debt And Capital Securities
RepaymentsOfLongTermDebtAndCapitalSecurities
|
13252000 | ||
| us-gaap |
Proceeds From Repayments Of Lines Of Credit
ProceedsFromRepaymentsOfLinesOfCredit
|
-677000 | ||
| us-gaap |
Proceeds From Repayments Of Lines Of Credit
ProceedsFromRepaymentsOfLinesOfCredit
|
581000 | ||
| us-gaap |
Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
|
10996000 | ||
| us-gaap |
Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
|
35000 | ||
| us-gaap |
Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
|
698000 | ||
| us-gaap |
Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
|
0 | ||
| us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
589000 | ||
| us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
12956000 | ||
| us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
11459000 | ||
| us-gaap |
Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
-62000 | ||
| us-gaap |
Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
-104000 | ||
| us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
-80000 | ||
| us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
-1871000 | ||
| CY2017Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
26474000 | |
| CY2016Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
17401000 | |
| CY2017Q3 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
15530000 | |
| cdna |
Business Acquisition Deferred Payment Consideration
BusinessAcquisitionDeferredPaymentConsideration
|
1064000 | ||
| cdna |
Shares Issued In Lieu Of Cash Payment
SharesIssuedInLieuOfCashPayment
|
0 | ||
| cdna |
Shares Issued In Lieu Of Cash Payment
SharesIssuedInLieuOfCashPayment
|
1145000 | ||
| cdna |
Accrued Interest Capitalized To Debt Principal
AccruedInterestCapitalizedToDebtPrincipal
|
0 | ||
| cdna |
Accrued Interest Capitalized To Debt Principal
AccruedInterestCapitalizedToDebtPrincipal
|
984000 | ||
| cdna |
Contingent Consideration Deferred Payment In Shares
ContingentConsiderationDeferredPaymentInShares
|
2689000 | ||
| cdna |
Contingent Consideration Deferred Payment In Shares
ContingentConsiderationDeferredPaymentInShares
|
0 | ||
| CY2018Q3 | us-gaap |
Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
|
192000 | |
| CY2017Q4 | us-gaap |
Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
|
9579000 | |
| us-gaap |
Use Of Estimates
UseOfEstimates
|
<div> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Use of Estimates</font></p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities and the reported amounts of revenues and expenses in the unaudited condensed consolidated financial statements and accompanying notes. On an ongoing basis, management evaluates its estimates, including those related to (i) variable transaction price consideration related to contracts with customers, (ii) the determination of the accruals for clinical studies, (iii) the fair value of assets and liabilities acquired in business combinations, including contingent consideration, (iv) inventory valuation, (v) the valuation of common stock warrant liability, (vi) the fair value of embedded derivatives, (vii) measurement of stock-based compensation expense, (viii) the determination of the valuation allowance and estimated tax benefit associated with deferred tax assets and net deferred tax liability, (ix) any impairment of long-lived assets, including in-process technology and goodwill, and (x) legal contingencies. Actual results could differ from those estimates.</p></div> | ||
| us-gaap |
Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
|
<div> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Concentrations of Credit Risk and Other Risks and Uncertainties</font></p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the nine months ended September 30, 2018 and 2017, approximately 47% and 27%, respectively, of total revenue was derived from Medicare.<font style="color:#000000;"> No other payers or customers represented more than 10% of total revenue for these periods.</font></p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At September 30, 2018 and December 31, 2017, approximately 29% and 16%, respectively, of accounts receivable was due from Medicare. No other payer or customer represented more than 10% of accounts receivable on either September 30, 2018 or December 31, 2017. </p></div> | ||
| us-gaap |
Revenue Recognition Sales Of Goods
RevenueRecognitionSalesOfGoods
|
<div> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Product Revenue</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Product revenue is recognized from the sale of products to end-users, distributors and strategic partners when all revenue recognition criteria are satisfied. The Company generally has a contract or a purchase order from a customer with the specified required terms of order, including the number of products ordered. Transaction prices are determinable and products are delivered and risk of loss passed to the customer upon either shipping or delivery, as per the terms of the agreement. There are no further performance obligations related to a contract and revenue is recognized at the point of delivery consistent with the terms of the contract or purchase order.</p></div> | ||
| us-gaap |
Revenue Recognition Multiple Element Arrangements
RevenueRecognitionMultipleElementArrangements
|
<div> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">License and Other Revenue</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company generates revenue from license agreements. License agreements may include non-refundable upfront payments, partial or complete reimbursement of research and development costs, contingent payments based on the occurrence of specified events under the agreements, license fees and royalties on sales of products or product candidates if they are successfully commercialized. The Company’s performance obligations under the agreements may include the transfer of intellectual property rights in the form of licenses, obligations to provide research and development services and obligations to participate on certain development committees. The Company makes judgments to determine if performance obligations are distinct or should be combined and the transaction price allocated to each performance obligation, which affect the periods over which revenue is recognized. The Company periodically reviews its estimated periods of performance based on the progress under each arrangement and accounts for the impact of any change in estimated periods of performance on a prospective basis. The Company constrains variable consideration, such as milestones, if it is probable that a significant portion of revenue would be reversed. The Company’s deferred revenue relates to one performance obligation, which should be recognized over time.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company did not recognize any revenue connected with milestones during the three or nine months ended September 30, 2018 or 2017.</p></div> | ||
| CY2018Q3 | us-gaap |
Number Of Reportable Segments
NumberOfReportableSegments
|
1 | |
| CY2018Q3 | us-gaap |
Debt And Capital Lease Obligations
DebtAndCapitalLeaseObligations
|
13400000 | |
| CY2018Q3 | us-gaap |
Revenue Recognition Milestone Method Revenue Recognized
RevenueRecognitionMilestoneMethodRevenueRecognized
|
0 | |
| us-gaap |
Revenue Recognition Milestone Method Revenue Recognized
RevenueRecognitionMilestoneMethodRevenueRecognized
|
0 | ||
| CY2017Q3 | us-gaap |
Revenue Recognition Milestone Method Revenue Recognized
RevenueRecognitionMilestoneMethodRevenueRecognized
|
0 | |
| us-gaap |
Revenue Recognition Milestone Method Revenue Recognized
RevenueRecognitionMilestoneMethodRevenueRecognized
|
0 | ||
| CY2018Q3 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
37154293 | |
| CY2017Q3 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
22526615 | |
| us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
34134138 | ||
| us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
21765292 | ||
| CY2018Q3 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.54 | |
| CY2017Q3 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.63 | |
| us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-1.26 | ||
| us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-1.09 | ||
| CY2018Q3 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
4225028 | |
| CY2017Q3 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
13381168 | |
| us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
4225028 | ||
| us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
13381168 | ||
| cdna |
Fair Value Measurements Inter Transfers Between Levels
FairValueMeasurementsInterTransfersBetweenLevels
|
0 | ||
| CY2017 | cdna |
Fair Value Measurements Inter Transfers Between Levels
FairValueMeasurementsInterTransfersBetweenLevels
|
0 | |
| CY2018Q3 | us-gaap |
Number Of Operating Segments
NumberOfOperatingSegments
|
1 | |
| CY2018Q3 | us-gaap |
Number Of Reporting Units
NumberOfReportingUnits
|
1 | |
| CY2018Q3 | us-gaap |
Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
|
29462000 | |
| CY2018Q3 | us-gaap |
Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
|
43077000 | |
| CY2018Q3 | cdna |
Intangible Assets Excluding Goodwill Accumulated Amortization
IntangibleAssetsExcludingGoodwillAccumulatedAmortization
|
6407000 | |
| CY2018Q3 | cdna |
Intangible Assets Excluding Goodwill Foreign Currency Translation Gain Loss
IntangibleAssetsExcludingGoodwillForeignCurrencyTranslationGainLoss
|
2386000 | |
| us-gaap |
New Date Of Annual Goodwill Impairment Test
NewDateOfAnnualGoodwillImpairmentTest
|
On January 1, 2017, the Company adopted ASU 2017-04, which eliminated the Step 2 requirement of the goodwill impairment test. Instead, the goodwill impairment test is performed by comparing the fair value of a reporting unit with its carrying amount. The Company determined that the decrease in its market capitalization in the first quarter of 2017 constituted an indicator of impairment and therefore a goodwill impairment test was completed as of March 31, 2017. | ||
| CY2018Q3 | us-gaap |
Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
|
38255000 | |
| CY2018Q3 | us-gaap |
Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
|
6407000 | |
| CY2018Q3 | cdna |
Finite Lived Intangible Foreign Currency Translation
FiniteLivedIntangibleForeignCurrencyTranslation
|
2386000 | |
| CY2018Q3 | us-gaap |
Finite Lived Intangible Assets Amortization Expense Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
|
2839000 | |
| CY2018Q3 | cdna |
Finite Lived Intangible Assets Amortization Expense Year Six
FiniteLivedIntangibleAssetsAmortizationExpenseYearSix
|
2839000 | |
| CY2018Q3 | cdna |
Finite Lived Intangible Assets Amortization Expense After Year Six
FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearSix
|
14223000 | |
| CY2018Q3 | us-gaap |
Inventory Finished Goods
InventoryFinishedGoods
|
2200000 | |
| CY2017Q4 | us-gaap |
Inventory Finished Goods
InventoryFinishedGoods
|
2569000 | |
| CY2017Q4 | us-gaap |
Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
|
37875000 | |
| CY2017Q4 | us-gaap |
Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
|
4166000 | |
| CY2017Q4 | cdna |
Finite Lived Intangible Foreign Currency Translation
FiniteLivedIntangibleForeignCurrencyTranslation
|
570000 | |
| CY2017Q4 | us-gaap |
Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
|
33139000 | |
| CY2018Q3 | us-gaap |
Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
|
600000 | |
| CY2017Q3 | us-gaap |
Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
|
600000 | |
| us-gaap |
Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
|
1900000 | ||
| us-gaap |
Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
|
1800000 | ||
| CY2018Q3 | us-gaap |
Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
|
748000 | |
| CY2018Q3 | us-gaap |
Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
|
2987000 | |
| CY2018Q3 | us-gaap |
Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
|
2987000 | |
| CY2018Q3 | us-gaap |
Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
|
2839000 | |
| CY2018Q3 | us-gaap |
Inventory Work In Process
InventoryWorkInProcess
|
1272000 | |
| CY2017Q4 | us-gaap |
Inventory Work In Process
InventoryWorkInProcess
|
1471000 | |
| CY2018Q3 | us-gaap |
Inventory Raw Materials And Supplies
InventoryRawMaterialsAndSupplies
|
1149000 | |
| CY2017Q4 | us-gaap |
Inventory Raw Materials And Supplies
InventoryRawMaterialsAndSupplies
|
1489000 | |
| CY2018Q3 | cdna |
Accrued Clinical And Cost Of Other Studies Current
AccruedClinicalAndCostOfOtherStudiesCurrent
|
1740000 | |
| CY2017Q4 | cdna |
Accrued Clinical And Cost Of Other Studies Current
AccruedClinicalAndCostOfOtherStudiesCurrent
|
1115000 | |
| CY2018Q3 | cdna |
Accrued Sample Processing Fees
AccruedSampleProcessingFees
|
652000 | |
| CY2017Q4 | cdna |
Accrued Sample Processing Fees
AccruedSampleProcessingFees
|
633000 | |
| CY2018Q3 | us-gaap |
Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
|
590000 | |
| CY2017Q4 | us-gaap |
Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
|
475000 | |
| CY2018Q3 | us-gaap |
Deferred Rent Credit Current
DeferredRentCreditCurrent
|
426000 | |
| CY2017Q4 | us-gaap |
Deferred Rent Credit Current
DeferredRentCreditCurrent
|
419000 | |
| CY2018Q3 | us-gaap |
Accrued Royalties Current
AccruedRoyaltiesCurrent
|
224000 | |
| CY2017Q4 | us-gaap |
Accrued Royalties Current
AccruedRoyaltiesCurrent
|
0 | |
| CY2018Q3 | cdna |
Customer Overpayments And Refunds Due
CustomerOverpaymentsAndRefundsDue
|
187000 | |
| CY2017Q4 | cdna |
Customer Overpayments And Refunds Due
CustomerOverpaymentsAndRefundsDue
|
270000 | |
| CY2018Q3 | us-gaap |
Capital Lease Obligations Current
CapitalLeaseObligationsCurrent
|
169000 | |
| CY2017Q4 | us-gaap |
Capital Lease Obligations Current
CapitalLeaseObligationsCurrent
|
13000 | |
| CY2018Q3 | cdna |
Accrued Software Implementation Costs
AccruedSoftwareImplementationCosts
|
0 | |
| CY2017Q4 | cdna |
Accrued Software Implementation Costs
AccruedSoftwareImplementationCosts
|
94000 | |
| CY2018Q3 | us-gaap |
Interest Payable Current
InterestPayableCurrent
|
0 | |
| CY2017Q4 | us-gaap |
Interest Payable Current
InterestPayableCurrent
|
81000 | |
| CY2018Q3 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
730000 | |
| CY2017Q4 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
635000 | |
| cdna |
Leases Expiration Period
LeasesExpirationPeriod
|
2020 | ||
| CY2018Q3 | us-gaap |
Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
|
600000 | |
| CY2017Q3 | us-gaap |
Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
|
400000 | |
| us-gaap |
Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
|
1500000 | ||
| us-gaap |
Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
|
1300000 | ||
| CY2018Q3 | us-gaap |
Capital Leases Future Minimum Payments Remainder Of Fiscal Year
CapitalLeasesFutureMinimumPaymentsRemainderOfFiscalYear
|
48000 | |
| CY2018Q3 | us-gaap |
Capital Leases Future Minimum Payments Due In Two Years
CapitalLeasesFutureMinimumPaymentsDueInTwoYears
|
193000 | |
| CY2018Q3 | us-gaap |
Capital Leases Future Minimum Payments Due In Three Years
CapitalLeasesFutureMinimumPaymentsDueInThreeYears
|
193000 | |
| CY2018Q3 | us-gaap |
Capital Leases Future Minimum Payments Due In Four Years
CapitalLeasesFutureMinimumPaymentsDueInFourYears
|
67000 | |
| CY2018Q3 | us-gaap |
Capital Leases Future Minimum Payments Due In Five Years
CapitalLeasesFutureMinimumPaymentsDueInFiveYears
|
0 | |
| CY2018Q3 | us-gaap |
Capital Leases Future Minimum Payments Due
CapitalLeasesFutureMinimumPaymentsDue
|
501000 | |
| CY2018Q3 | us-gaap |
Operating Leases Future Minimum Payments Remainder Of Fiscal Year
OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear
|
561000 | |
| CY2018Q3 | us-gaap |
Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
|
2139000 | |
| CY2018Q3 | us-gaap |
Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
|
2053000 | |
| cdna |
Description Of Agreement Expected Expiration Year
DescriptionOfAgreementExpectedExpirationYear
|
The agreement will expire at the later of the last-to-expire patent in the EEA or ten years from the first commercial sale of the test in the EEA, which occurred in 2014. | ||
| CY2013Q2 | cdna |
Upfront Payment In Cash
UpfrontPaymentInCash
|
387500 | |
| CY2013Q2 | cdna |
Upfront Payment In Cash
UpfrontPaymentInCash
|
408000 | |
| CY2018Q3 | cdna |
Revenues And Royalties Recognized
RevenuesAndRoyaltiesRecognized
|
10000 | |
| CY2018Q3 | us-gaap |
Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
|
10000 | |
| CY2018Q3 | us-gaap |
Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
|
7000 | |
| CY2018Q3 | us-gaap |
Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
|
4770000 | |
| CY2018Q3 | us-gaap |
Payments For Royalties
PaymentsForRoyalties
|
200000 | |
| us-gaap |
Payments For Royalties
PaymentsForRoyalties
|
400000 | ||
| CY2017Q4 | cdna |
Royalty Revenue Receivable
RoyaltyRevenueReceivable
|
0 | |
| CY2018Q3 | cdna |
Royalty Revenue Receivable
RoyaltyRevenueReceivable
|
0 | |
| CY2017Q3 | cdna |
Revenues And Royalties Recognized
RevenuesAndRoyaltiesRecognized
|
10000 | |
| cdna |
Revenues And Royalties Recognized
RevenuesAndRoyaltiesRecognized
|
29000 | ||
| cdna |
Revenues And Royalties Recognized
RevenuesAndRoyaltiesRecognized
|
29000 | ||
| CY2018Q3 | us-gaap |
Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
|
1616000 | |
| CY2017Q4 | us-gaap |
Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
|
4600000 | |
| CY2018Q3 | us-gaap |
Interest Payable Current And Noncurrent
InterestPayableCurrentAndNoncurrent
|
0 | |
| CY2017Q4 | us-gaap |
Interest Payable Current And Noncurrent
InterestPayableCurrentAndNoncurrent
|
300000 | |
| CY2018Q3 | cdna |
Long Term Debt Maturities Repayments In Year Four
LongTermDebtMaturitiesRepaymentsInYearFour
|
2025000 | |
| CY2018Q3 | cdna |
Long Term Debt Maturities Repayments In Year Five
LongTermDebtMaturitiesRepaymentsInYearFive
|
2700000 | |
| CY2018Q3 | cdna |
Long Term Debt Maturities Repayments After Year Five
LongTermDebtMaturitiesRepaymentsAfterYearFive
|
10275000 | |
| CY2018Q3 | cdna |
Long Term Debt Maturities Repayments
LongTermDebtMaturitiesRepayments
|
15000000 | |
| CY2018Q3 | us-gaap |
Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
|
100000 | |
| us-gaap |
Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
|
200000 | ||
| CY2018Q3 | cdna |
Purchase Of Common Stock Warrants Exercised
PurchaseOfCommonStockWarrantsExercised
|
2530000 | |
| cdna |
Purchase Of Common Stock Warrants Exercised
PurchaseOfCommonStockWarrantsExercised
|
2998000 | ||
| CY2017Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
|
156429 | |
| us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
|
1957075 | ||
| us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
|
16150 | ||
| us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
|
0 | ||
| cdna |
Share Based Compensation Arrangement By Share Based Payment Award Repurchases Of Common Stock Under Employee Incentive Plans
ShareBasedCompensationArrangementByShareBasedPaymentAwardRepurchasesOfCommonStockUnderEmployeeIncentivePlans
|
67656 | ||
| us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
|
901533 | ||
| cdna |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercised In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriod
|
0 | ||
| us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
|
27553 | ||
| us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
|
1817 | ||
| CY2018Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
|
562004 | |
| CY2017Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
1941473 | |
| cdna |
Share Based Compensation Arrangement By Share Based Payment Award Options Assumed From Acquisitions In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedFromAcquisitionsInPeriod
|
0 | ||
| us-gaap |
Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
|
281465 | ||
| CY2018Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
2532171 | |
| CY2017Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
4.21 | |
| cdna |
Share Based Compensation Arrangement By Share Based Payment Award Weighted Average Exercised Price Shares Reserved
ShareBasedCompensationArrangementByShareBasedPaymentAwardWeightedAverageExercisedPriceSharesReserved
|
0 | ||
| us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
|
12.06 | ||
| us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
|
2.09 | ||
| us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
|
5.19 | ||
| us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
|
3.55 | ||
| CY2018Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
7.23 | |
| us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
|
2600000 | ||
| CY2018Q3 | cdna |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingNumber
|
1024442 | |
| CY2018Q3 | cdna |
Share Based Compensation Arrangement By Share Based Payment Award Options Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingNumber
|
1329020 | |
| CY2018Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
|
2353462 | |
| cdna |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedWeightedAverageExercisePrice
|
4.96 | ||
| CY2018Q3 | cdna |
Share Based Compensation Arrangement By Share Based Payment Award Options Expected To Vest Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestWeightedAverageExercisePrice
|
8.85 | |
| cdna |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested Outstanding Weighted Average Remaining Contractual Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingWeightedAverageRemainingContractualTerm
|
P6Y7M2D | ||
| cdna |
Share Based Compensation Arrangement By Share Based Payment Award Options Expected To Vest Outstanding Weighted Average Remaining Contractual Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingWeightedAverageRemainingContractualTerm
|
P7Y2M12D | ||
| CY2018Q3 | cdna |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingAggregateIntrinsicValue
|
24478000 | |
| CY2018Q3 | cdna |
Share Based Compensation Arrangement By Share Based Payment Award Options Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingAggregateIntrinsicValue
|
26575000 | |
| CY2018Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
|
51053000 | |
| CY2018Q3 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
1860000 | |
| CY2017Q3 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
430000 | |
| us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
5078000 | ||
| us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
1316000 | ||
| us-gaap |
Employee Service Share Based Compensation Tax Benefit From Compensation Expense
EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
|
0 | ||
| us-gaap |
Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount
EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
|
0 | ||
| us-gaap |
Number Of Reportable Segments
NumberOfReportableSegments
|
2 |
